Excalibur Management Corp Has $496,000 Stake in Danaher Co. (NYSE:DHR)

Excalibur Management Corp decreased its holdings in Danaher Co. (NYSE:DHR) by 2.9% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,987 shares of the conglomerate’s stock after selling 60 shares during the period. Excalibur Management Corp’s holdings in Danaher were worth $496,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Gilbert & Cook Inc. increased its holdings in Danaher by 4.9% in the fourth quarter. Gilbert & Cook Inc. now owns 1,830 shares of the conglomerate’s stock worth $423,000 after buying an additional 86 shares during the last quarter. Accretive Wealth Partners LLC increased its holdings in Danaher by 12.9% in the fourth quarter. Accretive Wealth Partners LLC now owns 3,632 shares of the conglomerate’s stock worth $840,000 after buying an additional 414 shares during the last quarter. Gryphon Financial Partners LLC increased its holdings in Danaher by 19.1% in the fourth quarter. Gryphon Financial Partners LLC now owns 2,917 shares of the conglomerate’s stock worth $675,000 after buying an additional 468 shares during the last quarter. TrinityPoint Wealth LLC increased its holdings in Danaher by 12.4% in the fourth quarter. TrinityPoint Wealth LLC now owns 1,469 shares of the conglomerate’s stock worth $340,000 after buying an additional 162 shares during the last quarter. Finally, Hillsdale Investment Management Inc. increased its holdings in Danaher by 38.7% in the fourth quarter. Hillsdale Investment Management Inc. now owns 215 shares of the conglomerate’s stock worth $50,000 after buying an additional 60 shares during the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Stock Up 0.7 %

Shares of DHR stock opened at $276.06 on Tuesday. The stock has a market cap of $199.37 billion, a P/E ratio of 46.79, a price-to-earnings-growth ratio of 4.48 and a beta of 0.83. Danaher Co. has a one year low of $182.09 and a one year high of $281.70. The stock has a fifty day moving average price of $265.25 and a 200 day moving average price of $256.67. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.43 and a quick ratio of 1.04.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 EPS for the quarter, topping the consensus estimate of $1.57 by $0.15. The firm had revenue of $5.74 billion during the quarter, compared to analysts’ expectations of $5.59 billion. Danaher had a return on equity of 11.06% and a net margin of 16.94%. Danaher’s quarterly revenue was down 2.9% compared to the same quarter last year. During the same period last year, the business earned $2.05 earnings per share. Analysts predict that Danaher Co. will post 7.59 earnings per share for the current year.

Danaher Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, October 25th. Investors of record on Friday, September 27th will be given a $0.27 dividend. The ex-dividend date of this dividend is Friday, September 27th. This represents a $1.08 annualized dividend and a yield of 0.39%. Danaher’s dividend payout ratio (DPR) is currently 18.31%.

Insider Buying and Selling

In other Danaher news, SVP Georgeann Couchara sold 952 shares of Danaher stock in a transaction on Monday, August 26th. The stock was sold at an average price of $268.37, for a total transaction of $255,488.24. Following the completion of the transaction, the senior vice president now directly owns 4,212 shares of the company’s stock, valued at $1,130,374.44. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other Danaher news, SVP Brian W. Ellis sold 9,600 shares of Danaher stock in a transaction on Thursday, July 25th. The stock was sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the completion of the transaction, the senior vice president now directly owns 20,230 shares of the company’s stock, valued at $5,566,486.80. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Georgeann Couchara sold 952 shares of Danaher stock in a transaction on Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the transaction, the senior vice president now directly owns 4,212 shares of the company’s stock, valued at $1,130,374.44. The disclosure for this sale can be found here. Insiders sold a total of 39,659 shares of company stock valued at $11,042,433 over the last ninety days. 11.10% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of equities analysts recently commented on the company. Barclays increased their price objective on Danaher from $270.00 to $285.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 24th. Robert W. Baird increased their price target on Danaher from $271.00 to $278.00 and gave the company an “outperform” rating in a report on Wednesday, July 24th. Royal Bank of Canada reiterated an “outperform” rating and set a $300.00 price target on shares of Danaher in a report on Friday, September 6th. Stifel Nicolaus increased their price target on Danaher from $235.00 to $250.00 and gave the company a “hold” rating in a report on Wednesday, July 24th. Finally, StockNews.com downgraded Danaher from a “buy” rating to a “hold” rating in a report on Tuesday, June 25th. Seven analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. According to data from MarketBeat.com, Danaher presently has a consensus rating of “Moderate Buy” and a consensus target price of $278.94.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.